Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras (CALLAS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by National Cancer Institute, Naples
Information provided by (Responsible Party):
National Cancer Institute, Naples Identifier:
First received: July 24, 2012
Last updated: November 25, 2015
Last verified: November 2015
The purpose of this study is to describe the treatments received and outcomes of patients with metastatic colorectal cancer, what percentage of these patients have K-Ras mutation of the tumor, and to describe the costs of treatments. Information will also be collected regarding risk factors, variables among treatment centers and patients, and explorative analyses will be done to try to identify factors that impact prognosis and factors that predict tolerability and response to treatment.

Condition Phase
Metastatic Colorectal Cancer
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras

Resource links provided by NLM:

Further study details as provided by National Cancer Institute, Naples:

Primary Outcome Measures:
  • percentage of patients enrolled in a clinical trial [ Time Frame: two years ] [ Designated as safety issue: No ]
  • percentage of patients who undergo K-Ras mutation study [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Percentage of patients with K-Ras mutation [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • metastatic colorectal cancer treatments used in clinical practice, according to participating center [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • patient outcome according to K-Ras status [ Time Frame: two years ] [ Designated as safety issue: No ]
  • estimated costs per treatment per center [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • disease outcome per patient per treatment received [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • factors that influence patient prognosis [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    exploratory analyses

  • predictive factors for response to treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    exploratory analyses

Estimated Enrollment: 500
Study Start Date: October 2010
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
metastatic colorectal cancer


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients at participating Institutes who are candidate for first-line treatment of metastatic colorectal cancer

Inclusion Criteria:

  • Histologic diagnosis colorectal carcinoma
  • Metastatic disease
  • Signed informed consent

Exclusion Criteria:

  • Prior treatment of metastatic colorectal cancer
  • Refusal or incapability of providing informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01651013

Contact: Francesco Perrone, M.D., Ph.D. +39 081 5903571
Contact: Marilina Piccirillo, M.D. +39 081 5903383

A.O.G. Rummo Recruiting
Benevento, Italy
Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Entero-proctologico Recruiting
Napoli, Italy
Ospedale Civile Umberto I Recruiting
Nocera Inferiore, Italy
C:R.O. Regione Basilicata Ospedale Giustino Fortunato Recruiting
Rionero in Vulture, Italy
Sponsors and Collaborators
National Cancer Institute, Naples
Principal Investigator: R. V. Iaffaioli, M.D. National Cancer Institute, Naples
Principal Investigator: G. Nasti, M.D. National Cancer Institute, Naples
Principal Investigator: M. C. Piccirillo, M.D. National Cancer Institute, Naples
  More Information

Responsible Party: National Cancer Institute, Naples Identifier: NCT01651013     History of Changes
Other Study ID Numbers: CALLAS 
Study First Received: July 24, 2012
Last Updated: November 25, 2015
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on October 21, 2016